Management of Alcohol Dependence after Detoxification
Alcohol dependence is a major health problem associated with substantial social and healthcare costs. Until recently, the only available management options for maintaining abstinence in alcohol-dependent patients after detoxification were psychosocial/behavioural therapies (including self-help groups) and aversive therapies such as disulfiram. Although these approaches can reduce alcohol intake, their efficacy is limited and aversive therapy is associated with potentially serious adverse events and poor patient compliance.
A greater understanding of the neurobiology of alcohol dependence has resulted in the investigation of a range of agents with effects on the various neurotransmitters and neuromodulators involved in this condition. Acamprosate, a glutamatergic agent, and naltrexone, an opioid antagonist, have shown the most promise; acamprosate has been the most extensively studied.
Acamprosate is the first agent to be developed specifically for the prevention of relapse in detoxified alcohol-dependent patients. This well tolerates drug increases mean continuous alcohol abstinence rates, the cumulative duration of abstinence and the time to first alcoholic drink compared with placebo. Its efficacy may be enhanced by the addition of disulfiram.
Comparative trials with naltrexone and other active treatment approaches are required before the definitive position of acamprosate can be determined. In the meantime, acamprosate, as an adjunct to psychosocial/behavioural therapies (including counselling), can be considered a promising first-line pharmacological therapy for the maintenance of abstinence in detoxified alcohol-dependent patients.
KeywordsAdis International Limited Alcohol Dependence Naltrexone Buspirone Disulfiram
Unable to display preview. Download preview PDF.
- 2.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association, 1994: 176–181.Google Scholar
- 5.Schuckit MA. Alcohol and alcoholism. In: Wilson JD, Braunwald E, et al., editors. Harrison’s principles of internal medicine. 12th ed. vol. 2. USA: McGraw-Hill Inc., 1991: 2146–51.Google Scholar
- 11.Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral-symposium ESBRA. Stuttgart: Springer, 1995: 47–64.Google Scholar
- 21.Lesch OM, Walter H, Bonte W. Etiology of subgroups in chronic alcoholism and different mechanisms in transmitter systems. In: Palmer TN, editor. Alcoholism: a molecular Perspective. New York: Plenum Press,. 1991; 206: 145–60.Google Scholar
- 22.Heizer JE, Burnam A, McEvoy LT. Alcohol abuse and dependence. In: Robins CN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: Free Press, 1991: 81–115.Google Scholar
- 23.Grant BF, Harford TC, Dawson DA, et al. Epidemiologic bulletin no. 35: prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World. 1991; 18: 243–8.Google Scholar
- 27.Dongier M. Brain, alcohol and alcoholism treatment. Ann R Coll Phys Surg Can. 1993; 26(1): 26–8.Google Scholar
- 28.Rice DP. The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World. 1993; 17: 10–1.Google Scholar
- 29.Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental illness: 1985a. Report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse, and Mental Health Administration, US Department of Health and Human Services, San Francisco (CA): Institute for Health and Aging, University of California, 1990.Google Scholar
- 32.Rice DP. The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World. 1993; 17(1): 10–1.Google Scholar
- 37.Boismare F, Daoust M, Lhuintre JP, et al. Which GABA receptors are involved in the voluntary ethanol intake by rats? [abstract]. Alcohol Alcohol 1986; 21: A30.Google Scholar
- 39.Perlmutter SJ. Pharmacologic treatment of substance abuse. Child Adolesc Psychiatr Clin North Am. 1995; 4(2): 435–52.Google Scholar
- 48.Chick J. Emergent treatment concepts. Annu Rev Addict Res Treat. 1992; 2: 297–312.Google Scholar
- 59.Lipha. Campral, Prescribing information. European summary of product characteristics, Lyon, France, 1995.Google Scholar
- 62.Zieglgänsberger W, Hauser C, Putzke J, et al. Acamprosate reduces the enhanced excitability of central neurons following chronic alcohol intake [abstract]. Pharmacopsychiatry. 1995 Sep; 28: 231.Google Scholar
- 70.Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram for enhancing abstinence of chronic alcoholic patients during a one year post detoxication period [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. (Pt 2): 74S.Google Scholar
- 76.Tempesta E, Janiri L, Bignamini AA. The effectiveness and safety of calcium-acetylhomotaurinate (acamprosate) on the maintenance of abstinence in weaned alcoholics [abstract]. Eur Psychiatry 1994; 9 Suppl. 1: 203.Google Scholar
- 79.Sass H, Potgieter AS, Lehert P. Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract]. Alcohol Alcohol 1995; 30(4): 551.Google Scholar
- 82.Acamprosate helps maintain abstinence from alcohol after detoxification. Drug Ther Perspect 1997 Sep 1; 10 (5): 1–5.Google Scholar
- 83.Schädlich PK, Brecht JG. Cost-effectiveness of acamprosate in relapse prevention in alcoholism in Germany. ICAAA Congress, Amsterdam, 1996.Google Scholar